Post Cardiopulmonary Bypass Bleeding: An Introductory Review
J Extra Corpor Technol, 31 1 (1999) 23-36
Published online: 2023-08-14
Articles citing this article
The Citing articles tool gives a list of articles citing the current article.
The citing articles come from EDP Sciences database, as well as other publishers participating in CrossRef Cited-by Linking Program. You can set up your personal account to receive an email alert each time this article is cited by a new article (see the menu on the right-hand side of the abstract page).
Cited article:
This article has been cited by the following article(s):
Reoperation for bleeding after cardiac surgery
Vincent M. De La Porte, Gregory R. A. De Meyer, Tom Schepens, Walter Verbrugghe, Steven Laga, Mathias Allegaert, Pieter Mertens, Inez Rodrigus and Philippe G. JorensActa Chirurgica Belgica 122 (5) 312 (2022)
https://doi.org/10.1080/00015458.2020.1847463
783 (2020)
https://doi.org/10.1007/978-3-030-24174-2_86
771 (2014)
https://doi.org/10.1007/978-1-4471-4619-3_75
Comparison of the Quality of Life After Conventional Versus Off-Pump Coronary Artery Bypass Surgery
Emmanouil I. Kapetanakis, Sotiris C. Stamou, Kathleen R. Petro, Peter C. Hill, Steven W. Boyce, Ammar S. Bafi and Paul J. CorsoJournal of Cardiac Surgery 23 (2) 120 (2008)
https://doi.org/10.1111/j.1540-8191.2008.00590.x
Aortic dissection and hypothermic arrest in a Jehovah’s Witness patient: a case for recombinant factor VIIa?
Jenifer Ballen, Michael Raabe and Brian MuirheadCanadian Journal of Anesthesia/Journal canadien d'anesthésie 53 (4) 353 (2006)
https://doi.org/10.1007/BF03022498
Management of Antiplatelet Therapy for Minimization of Bleeding Risk Before Cardiac Surgery
Kyle A. Weant, Jeremy F. Flynn and Wendell S. AkersPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26 (11) 1616 (2006)
https://doi.org/10.1592/phco.26.11.1616
Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy
Henry Ekert, Christian Brizard, Robert Eyers, Andrew Cochrane and Robert HenningBlood Coagulation & Fibrinolysis 17 (5) 389 (2006)
https://doi.org/10.1097/01.mbc.0000233369.03358.c1
Safety of Recombinant Human Factor XIII in a Cynomolgus Monkey Model of Extracorporeal Blood Circulation
R. Ponce, K. Armstrong, K. Andrews, J. Hensler, K. Waggie, J. Heffernan, T. Reynolds and M. RoggeToxicologic Pathology 33 (6) 702 (2005)
https://doi.org/10.1080/15459620500330625
Off-Pump Myocardial Revascularization in a Diabetic Patient with Severe Hemophilia B and Impaired Left Ventricular Function: Hematological and Operative Strategies
Daniel Grandmougin, Maria-Christina Delolme, Jacqueline Reynaud and Xavier BarralJournal of Cardiac Surgery 20 (4) 366 (2005)
https://doi.org/10.1111/j.1540-8191.2005.2004108.x
811 (2005)
https://doi.org/10.1201/b14532-57
Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass
Viren N. Naik, C. David Mazer, David A. Latter, Jerome M. Teitel and Gregory M. T. HareCanadian Journal of Anesthesia/Journal canadien d'anesthésie 50 (6) 599 (2003)
https://doi.org/10.1007/BF03018648
Coronary artery bypass grafting surgery without the routine application of blood products: is it feasible?
Michaela Wilhelmi, Ulrich Franke, Tina Cohnert, Petra Weber, Jörg Kaukemüller, Stefan Fischer, Thorsten Wahlers and Axel HaverichEuropean Journal of Cardio-Thoracic Surgery 19 (5) 657 (2001)
https://doi.org/10.1016/S1010-7940(01)00648-0